OncoMatch/Clinical Trials/NCT03198052
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers
Is NCT03198052 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR for lung cancer.
Treatment: CAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR — The third generation of CAR-T cells that target GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR have been constructed respectively and their anti-cancer function has been verified by multiple in vitro and in vivo studies.Clinical studies will be performed to test the anti-cancer function of the these individual or combination of the CAR-T cells for immunotherapy of human cancer patients with GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFβ, HER2, Lewis-Y, AXL, or EGFR expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR -CAR-T cell immunotherapy on human cancers will firstly be tested.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: GPC3 protein expression
cancer that expresses GPC3 protein
Required: MSLN protein expression
cancer that expresses Mesothelin protein
Required: CLDN18 protein expression
cancer that expresses Claudin18.2 protein
Required: GUCY2C protein expression
cancer that expresses GUCY2C protein
Required: CD276 protein expression
cancer that expresses B7-H3 protein
Required: PSCA protein expression
cancer that expresses PSCA protein
Required: FOLH1 protein expression
cancer that expresses PSMA protein
Required: MUC1 protein expression
cancer that expresses MUC1 protein
Required: TGFB1 protein expression
cancer that expresses TGFβ protein
Required: HER2 (ERBB2) protein expression
cancer that expresses HER2 protein
Required: FUT3 Lewis-Y protein expression
cancer that expresses Lewis-Y protein
Required: AXL protein expression
cancer that expresses AXL protein
Required: EGFR protein expression
cancer that expresses EGFR protein
Prior therapy
Cannot have received: gene therapy
Lab requirements
Kidney function
Liver function
Cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify